Tommi Kainu, who currently holds the position of chief business officer and executive vice president at Bavarian Nordic, has resigned, but he will continue to support the company until the end of November 2021, according to Bavarian Nordic's press release on Friday morning.
"Tommi joined Bavarian Nordic to build industry partnerships and pave the way for a commercial transformation of the company. With the successful acquisition of Encepur and Rabipur and the establishment of the commercial organization, these main objectives have been completed," stated Bavarian Nordic President & CEO Paul Chaplin in the statement.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Genmab to submit cancer candidate epcoritamab to the FDA before year-end
The US Food and Drug Administration will receive a marketing authorization application from Genmab and its partner Abbvie in the second half of this year.
Bavarian Nordic is working with EMA on monkeypox vaccine label expansion
Bavarian Nordic’s smallpox vaccine Imvanex has previously been used off-label to protect close contacts from monkeypox in several countries. The Danish vaccine firm is now working with the EMA to expand the label in an ”accelerated process.”
Leo Pharma eczema treatment recommended in two UK countries
After postponing the decision in April, the British medicines council NICE has now ruled that Adtralza can be recommended to treat atopic dermatitis.
Fujifilm invests USD 1.5bn in Danish factory
Japanese firm Fujifilm Diosynth Biotechnologies is investing DKK 11bn (USD 1.5bn) in its factor in Northern Zealand, Denmark. The expansion will provide 450 jobs.
Life science firms are planning USD 6.3bn construction spree in Denmark
Fujifilm’s expansion to its factory in Hillerød means that the life science sector has announced DKK 12bn (USD 1.7bn) in facility investments in Denmark since May.
Director Regulatory Affairs 
Senior Manager/Associate Director, Global Regulatory Affairs, CMC 
Antibody Engineering Scientist 
Key Account Manager Vision Care, Nordic 
Device Associate Director/Senior Project Leader 
Global Learning Specialist 
Corporate Quality Compliance Specialists 
QA Specialist for Product Equipment Qualification 
Principal Scientist – Pharmacology 
Clinical Project Leader/ Sr. Clinical Trial Manager – make a difference and join our mission to bring our IL-22 lead program to patients 
Project Managers keep all of us healthy